摘要
目的评估高龄患者择期行经皮冠状动脉介入治疗(PCI)术中应用比伐卢定的安全性及有效性。方法选取2013年1月至2014年7月在沈阳军区总医院择期行PCI术的高龄冠心病患者298例,根据术中应用抗凝药情况分为肝素组和比伐卢定组,每组各149例。观察并比较两组患者术后30 d、1年内净不良事件(NACE)的发生情况。结果与肝素组比较,比伐卢定组术后30 d内全部出血事件发生率(6.7%比2.0%)及术后1年内NACE事件发生率(16.8%比6.7%)均显著下降,差异均有统计学意义(P<0.05)。比伐卢定组术后30 d内NACE事件发生率(9.4%比4.0%)及术后1年内出血事件发生率(8.1%比3.4%)均低于肝素组,但差异无统计学意义(P>0.05)。结论高龄患者非急诊PCI术中应用比伐卢定可降低出血风险,且不增加缺血风险。
Objective To evaluate the efficiency and safety of bivalirudin in elderly patients undergoing percutaneous coronary intervention（PCI）.Methods A retrospective study was performed on 298 cases of elderly patients underwent selective PCI from January2013 to July 2014.According to application of anticoagulants,patients were divided into the heparin group and the bivalirudin group,with 149 cases in each group.The incidence of the net adverse clinical events（NACE） in 30 days and 1 year were compared between the two groups.Results The incidence of 30 days bleeding（6.7% versus 2.0%） and 1-year NACE（16.8% versus 6.7%） in the bivalirudin group were significantly lower than those of the heparin group（P〈0.05）.The incidence of 30 days NACE（9.4% versus4.0%） and 1-year bleeding（8.1% versus 3.4%） in the bivalirudin group were lower than those in the heparin group without statistically significant difference（P〈0.05）.Conclusion Bivalirudin in the non-emergency elderly patients during PCI can reduce the risk of bleeding without increasing the risk of ischemia.
出处
《临床军医杂志》
CAS
2017年第11期1101-1104,共4页
Clinical Journal of Medical Officers
基金
国家"十三五"重点研发计划项目(2016YFC1301300)
关键词
高龄
经皮冠状动脉介入术
抗凝
比伐卢定
Elderly patients
Percutaneous coronary intervention
Antieoagulation
Bivalirudin
